About Us
Our People
Board of Directors
Our Product
In Development
Mission
Investors
Careers
Contact
Contact Us
Media Contact
Investor Contact
Investors
Investors Home
Stock Quote
Stock Information
Historical Stock Price
News Releases
Events and Presentations
SEC Filings
Analyst Coverage
Corporate Governance
Board of Directors
Charters & Code of Ethics
FAQs
Investor Contacts & Alerts
Investors Home
Stock Quote
News Releases
Events and Presentations
SEC Filings
Analyst Coverage
Corporate Governance
FAQs
Investor Contacts & Alerts
News Releases
Year
All Years
2021
2020
2019
2018
2017
2016
2015
2014
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Aug 3, 2020
Evofem Biosciences' CEO Saundra Pelletier Named to PharmaVOICE100 - The Most Inspiring People in Life Sciences
Jul 23, 2020
Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020
-- Conference Call Scheduled for 11:00 a.m. EDT --
Jul 15, 2020
Evofem Biosciences Announces Peer-Reviewed Publication of the Pivotal Phase 3 AMPOWER Study Results For Phexxi™ (lactic acid, citric acid and potassium bitartrate) in Contraception
Jul 1, 2020
Evofem Biosciences Issues Mid-Year 2020 Letter to Stockholders
- On-Track for September Launch of Phexxi™, the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel -
Jun 2, 2020
Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock
Show
5
10
25
50
100
per page
«
1
…
4
5
6
7
8
9
10
…
25
»